βarrestins in cardiac G protein-coupled receptor signaling and function: Partners in crime or "good cop, bad cop"?

International Journal of Molecular Sciences

Volumn 14, Issue 12, 2013, Pages 24726-24741

  Lymperopoulos, Anastasios ^a   Negussie, Shmuel ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

arrestins; Adrenergic receptors; Angiotensin ii receptors; Desensitization; GPCR; Heart; Signal transduction

Indexed keywords

3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; ADENYLATE CYCLASE; ANGIOTENSIN 1 RECEPTOR; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ARRESTIN; BETA ARRESTIN 1; BETA ARRESTIN 2; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CARVEDILOL; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE 2; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN BETA GAMMA COMPLEX; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; ISOETARINE; ISOPRENALINE; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; STAT PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; DESENSITIZATION; DOWN REGULATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART PROTECTION; HEART RATE; HEART VENTRICLE HYPERTROPHY; INFLAMMATION; MUTATION; NONHUMAN; PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ARRESTINS; HUMANS; MYOCARDIUM; RECEPTORS, ADRENERGIC; RECEPTORS, ANGIOTENSIN; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84890957716     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141224726     Document Type: Review

References (65)

1. Lymperopoulos, A.; Bathgate, A. Arrestins in the cardiovascular system. Prog. Mol. Biol. Transl. Sci. 2013, 118, 297-334
2. Kenakin, T. Making receptors a reality: The 2012 Nobel Prize in Chemistry. Trends Pharmacol. Sci. 2013, 34, 2-5
3. Lymperopoulos, A.; Rengo, G.; Koch, W.J. Adrenergic nervous system in heart failure: Pathophysiology and therapy. Circ. Res. 2013, 113, 739-753
4. Siryk-Bathgate, A.; Dabul, S.; Lymperopoulos, A. Current and future G protein-coupled receptor signaling targets for heart failure therapy. Drug Des. Dev. Ther. 2013, 7, 1209-1222
5. Lymperopoulos, A. Physiology and pharmacology of the cardiovascular adrenergic system. Front. Physiol. 2013, 4, 240
6. Lymperopoulos, A. β-arrestin biased agonism/antagonism at cardiovascular seven transmembrane-spanning receptors. Curr. Pharm. Des. 2012, 18, 192-198
7. Lymperopoulos, A.; Rengo, G.; Koch, W.J. GRK2 inhibition in heart failure: Something old, something new. Curr. Pharm. Des. 2012, 18, 186-191
8. Gurevich, V.V.; Gurevich, E.V. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol. Ther. 2006, 110, 465-502
9. Shukla, A.K.; Violin, J.D.; Whalen, E.J.; Gesty-Palmer, D.; Shenoy, S.K.; Lefkowitz, R.J. Distinct conformational changes in β-arrestin report biased agonism at seven-transmembrane receptors. Proc. Natl. Acad. Sci. USA 2008, 105, 9988-9993
10. Gurevich, V.V.; Pals-Rylaarsdam, R.; Benovic, J.L.; Hosey, M.M.; Onorato, J.J. Agonist-receptor-arrestin, an alternative ternary complex with high agonist affinity. J. Biol. Chem. 1997, 272, 28849-28852
11. Luttrell, L.M.; Gesty-Palmer, D. Beyond desensitization: Physiological relevance of arrestin dependent signaling. Pharmacol. Rev. 2010, 62, 305-330
12. Ferguson, S.S. Evolving concepts in G protein-coupled receptor endocytosis: The role in receptor desensitization and signaling. Pharmacol. Rev. 2001, 53, 1-24
13. Oakley, R.H.; Laporte, S.A.; Holt, J.A.; Caron, M.G.; Barak, L.S. Differential affinities of visual arrestin, βarrestin1, and βarrestin2 for G protein-coupled receptors delineate two major classes of receptors. J. Biol. Chem. 2000, 275, 17201-17210
14. Charest, P.G.; Terrillon, S.; Bouvier, M. Monitoring agonist-promoted conformational changes of β-arrestin in living cells by intramolecular BRET. EMBO Rep. 2005, 6, 334-340
15. Daaka, Y.; Luttrell, L.M.; Lefkowitz, R.J. Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390, 88-91
16. Communal, C.; Singh, K.; Sawyer, D.B.; Colucci, W.S. Opposing effects of β1- and β2-aadrenergic receptors on cardiac myocyte apoptosis: Role of a pertussis toxin-sensitive G protein. Circulation 1999, 100, 2210-2212
17. Chesley, A.; Lundberg, M.S.; Asai, T.; Xiao, R.P.; Ohtani, S.; Lakatta, E.G.; Crow, M.T. The β2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gidependent coupling to phosphatidylinositol 3-kinase. Circ. Res. 2000, 87, 1172-1179
18. Zhu, W.Z.; Zheng, M.; Koch, W.J.; Lefkowitz, R.J.; Kobilka, B.K.; Xiao, R.P. Dual modulation of cell survival and cell death by β2-adrenergic signalling in adult mouse cardiomyocytes. Proc. Natl. Acad. Sci. USA 2001, 98, 1607-1612
19. Dorn, G.W.; Tepe, N.M.; Lorenz, J.N.; Koch, W.J.; Liggett, S.B. Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. Proc. Natl. Acad. Sci. USA 1999, 96, 6400-6405
20. Conner, D.A.; Mathier, M.A.; Mortensen, R.M.; Christe, M.; Vatner, S.F.; Seidman, C.E.; Seidman, J.G. β-Arrestin1 knockout mice appear normal but demonstrate altered cardiac responses to β-adrenergic stimulation. Circ. Res. 1997, 81, 1021-1026
21. Xiang, Y.; Kobilka, B.K. Myocyte adrenoceptor signaling pathways. Science 2003, 300, 1530-1532
22. Bristow, M.R. β-adrenergic receptor blockade in chronic heart failure. Circulation 2000, 101, 558-569
23. Packer, M.; Bristow, M.R.; Cohn, J.N.; Colucci, W.S.; Fowler, M.B.; Gilbert, E.M.; Shusterman, N.H. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 1996, 334, 1349-1355
24. Noma, T.; Lemaire, A.; Naga Prasad, S.V.; Barki-Harrington, L.; Tilley, D.G.; Chen, J.; le Corvoisier, P.; Violin, J.D.; Wei, H.; Lefkowitz, R.J.; et al. β-arrestin-mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J. Clin. Invest. 2007, 117, 2445-2458
25. Tilley, D.G. G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circ. Res. 2011, 109, 217-230
26. Noor, N.; Patel, C.B.; Rockman, H.A. β-arrestin: A signaling molecule and potential therapeutic target for heart failure. J. Mol. Cell. Cardiol. 2011, 51, 534-41
27. Bathgate-Siryk, A.; Dabul, S.; Pandya, K.; Walklett, K.; Rengo, G.; Cannavo, A.; de Lucia, C.; Liccardo, D.; Gao, E.; Leosco, D.; et al. Negative impact of β-arrestin-1 on post-myocardial infarction heart failure via cardiac and adrenal-dependent neurohormonal mechanisms. Hypertension 2013, doi:10.1161/HYPERTENSIONAHA.113.02043
28. Bers, D.M. Calcium cycling and signaling in cardiac myocytes. Annu. Rev. Physiol. 2008, 70, 23-49
29. Kho, C.; Lee, A.; Jeong, D.; Oh, J.G.; Chaanine, A.H.; Kizana, E.; Park, W.J.; Hajjar, R.J. SUMO1-dependent modulation of SERCA2a in heart failure. Nature 2011, 477, 601-605
30. Lymperopoulos, A. Nova Southeastern University, Unpublished Observation, 2013
31. Mangmool, S.; Shukla, A.K.; Rockman, H.A. β-Arrestin-dependent activation of Ca2+/calmodulin kinase II after β1-adrenergic receptor stimulation. J. Cell Biol. 2010, 189, 573-587
32. Anderson, M.E. CaMKII and a failing strategy for growth in heart. J. Clin. Invest. 2009, 119, 1082-1085
33. Xiao, R.P.; Zhu, W.; Zheng, M.; Chakir, K.; Bond, R.; Lakatta, E.G.; Cheng, H. Subtype-specific β-adrenoceptor signaling pathways in the heart and their potential clinical implications. Trends Pharmacol. Sci. 2004, 25, 358-365
34. Luttrell, L.M.; Roudabush, F.L.; Choy, E.W.; Miller, W.E.; Field, M.E.; Pierce, K.L.; Lefkowitz, R.J. Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds. Proc. Natl. Acad. Sci. USA 2001, 98, 2449-2454
35. Witherow, D.S.; Garrison, T.R.; Miller, W.E.; Lefkowitz, R.J. β-Arrestin inhibits NF-κB activity by means of its interaction with the NF-κB inhibitor IkappaBalpha. Proc. Natl. Acad. Sci. USA 2004, 101, 8603-8607
36. Gao, H.; Sun, Y.; Wu, Y.; Luan, B.; Wang, Y.; Qu, B.; Pei, G. Identification of β-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-κB pathways. Mol. Cell. 2004, 14, 303-317
37. Richter, W.; Day, P.; Agrawal, R.; Bruss, M.D.; Granier, S.; Wang, Y.L.; Rasmussen, S.G.; Horner, K.; Wang, P.; Lei, T.; et al. Signaling from β1- and β2-adrenergic receptors is defined by differential interactions with PDE4. EMBO J. 2008, 27, 384-393
38. Xiang, Y.; Naro, F.; Zoudilova, M.; Jin, S.L.; Conti, M.; Kobilka, B. Phosphodiesterase 4D is required for β2-adrenoceptor subtype-specific signaling in cardiac myocytes. Proc. Natl. Acad. Sci. USA 2005, 102, 909-914
39. Salazar, N.C.; Vallejos, X.; Siryk, A.; Rengo, G.; Cannavo, A.; Liccardo, D.; de Lucia, C.; Gao, E.; Leosco, D.; Koch, W.J.; et al. GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility. Cell Commun. Signal. 2013, 11, 64
40. Houslay, M.D.; Baillie, G.S.; Maurice, D.H. cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: A molecular toolbox for generating compartmentalized cAMP signaling. Circ. Res. 2007, 100, 950-966
41. Drake, M.T.; Violin, J.D.; Whalen, E.J.; Wisler, J.W.; Shenoy, S.K.; Lefkowitz, R.J. β-arrestin-biased agonism at the β2-adrenergic receptor. J. Biol. Chem. 2008, 283, 5669-5676
42. Wisler, J.W.; DeWire, S.M.; Whalen, E.J.; Violin, J.D.; Drake, M.T.; Ahn, S.; Shenoy, S.K.; Lefkowitz, R.J. A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling. Proc. Natl. Acad. Sci. USA 2007, 104, 16657-16662
43. Billet, S.; Aguilar, F.; Baudry, C.; Clauser, E. Role of angiotensin II AT1 receptor activation in cardiovascular diseases. Kidney Int. 2008, 74, 1379-1384
44. Balmforth, A.J.; Shepherd, F.H.; Warburton, P.; Ball, S.G. Evidence of an important and direct role for protein kinase C in agonist-induced phosphorylation leading to desensitization of the angiotensin AT1A receptor. Br. J. Pharmacol. 1997, 122, 1469-1477
45. Olivares-Reyes, J.A.; Smith, R.D.; Hunyady, L.; Shah, B.H.; Catt, K.J. Agonist-induced signaling, desensitization, and internalization of a phosphorylation-deficient AT1A angiotensin receptor. J. Biol. Chem. 2001, 276, 37761-37768
46. Thomas, W.G.; Thekkumkara, T.J.; Baker, K.M. Cardiac effects of AII. AT1A receptor signaling, desensitization, and internalization. Adv. Exp. Med. Biol. 1996, 396, 59-69
47. Zhai, P.; Yamamoto, M.; Galeotti, J.; Liu, J.; Masurekar, M.; Thaisz, J.; Irie, K.; Holle, E.; Yu, X.; Kupershmidt, S.; et al. Cardiac-specific overexpression of AT1 receptor mutant lacking G αq/G α i coupling causes hypertrophy and bradycardia in transgenic mice. J. Clin. Invest. 2005, 115, 3045-3056
48. Holloway, A.C.; Qian, H.; Pipolo, L.; Ziogas, J.; Miura, S.; Karnik, S.; Southwell, B.R.; Lew, M.J.; Thomas, W.G. Side-chain substitutions within angiotensin II reveal different requirements for signaling, internalization, and phosphorylation of type 1A angiotensin receptors. Mol. Pharmacol. 2002, 61, 768-777
49. Rajagopal, K.; Whalen, E.J.; Violin, J.D.; Stiber, J.A.; Rosenberg, P.B.; Premont, R.T.; Coffman, T.M.; Rockman, H.A.; Lefkowitz, R.J. β-arrestin2-mediated inotropic effects of the angiotensin II type 1A receptor in isolated cardiac myocytes. Proc. Natl. Acad. Sci. USA 2006, 103, 16284-16289
50. Mishra, S.; Ling, H.; Grimm, M.; Zhang, T.; Bers, D.M.; Brown, J.H. Cardiac hypertrophy and heart failure development through Gq and CaM kinase II signaling. J. Cardiovasc. Pharmacol. 2010, 56, 598-603
51. Dorn, G.W., II; Force, T. Protein kinase cascades in the regulation of cardiac hypertrophy. J. Clin. Invest. 2005, 115, 527-537
52. Kukkonen, J.P. Regulation of receptor-coupling to (multiple) G proteins. A challenge for basic research and drug discovery. Recept. Channels 2004, 10, 167-183
53. Zidar, D.A.; Violin, J.D.; Whalen, E.J.; Lefkowitz, R.J. Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands. Proc. Natl. Acad. Sci. USA 2009, 106, 9649-9654
54. Aplin, M.; Christensen, G.L.; Schneider, M.; Heydorn, A.; Gammeltoft, S.; Kjølbye, A.L.; Sheikh, S.P.; Hansen, J.L. Differential extracellular signal-regulated kinases 1 and 2 activation by the angiotensin type 1 receptor supports distinct phenotypes of cardiac myocytes. Basic Clin. Pharmacol. Toxicol. 2007, 100, 296-301
55. Boerrigter, G.; Lark, M.W.; Whalen, E.J.; Soergel, D.G.; Violin, J.D.; Burnett, J.C., Jr. Cardiorenal actions of TRV120027, a novel β-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: A novel therapeutic strategy for acute heart failure. Circ. Heart Fail. 2011, 4, 770-778
56. Rakesh, K.; Yoo, B.; Kim, I.M.; Salazar, N.; Kim, K.S.; Rockman, H.A. β-Arrestin-biased agonism of the angiotensin receptor induced by mechanical stress. Sci. Signal. 2010, 3, ra46
57. Lymperopoulos, A.; Rengo, G.; Funakoshi, H.; Eckhart, A.D.; Koch, W.J. Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure. Nat. Med. 2007, 13, 315-323
58. Lymperopoulos, A.; Rengo, G.; Zincarelli, C.; Kim, J.; Soltys, S.; Koch, W.J. An adrenal β-arrestin 1-mediated signaling pathway underlies angiotensin II-induced aldosterone production in vitro and in vivo. Proc. Natl. Acad. Sci. USA 2009, 106, 5825-5830
59. Lymperopoulos, A.; Rengo, G.; Zincarelli, C.; Kim, J.; Koch, W.J. Adrenal β-arrestin 1 inhibition in vivo attenuates post-myocardial infarction progression to heart failure and adverse remodeling via reduction of circulating aldosterone levels. J. Am. Coll. Cardiol. 2011, 57, 356-365
60. Hasseldine, A.R.; Harper, E.A.; Black, J.W. Cardiac-specific overexpression of human β2 adrenoceptors in mice exposes coupling to both Gs and Gi proteins. Br. J. Pharmacol. 2003, 138, 1358-1366
61. DeWire, S.M.; Ahn, S.; Lefkowitz, R.J.; Shenoy, S.K. β-arrestins and cell signaling. Annu. Rev. Physiol. 2007, 69. 483-510
62. Liu, J.J.; Horst, R.; Katritch, V.; Stevens, R.C.; Wüthrich, K. Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science 2012, 335, 1106-1110
63. Kim, J.; Ahn, S.; Ren, X.R.; Whalen, E.J.; Reiter, E.; Wei, H.; Lefkowitz, R.J. Functional antagonism of different G protein-coupled receptor kinases for β-arrestin-mediated angiotensin II receptor signaling. Proc. Natl. Acad. Sci. USA 2005, 102, 1442-1447
64. DeWire, S.M.; Violin, J.D. Biased ligands for better cardiovascular drugs: Dissecting G-protein-coupled receptor pharmacology. Circ. Res. 2011, 109, 205-216
65. Violin, J.D.; Soergel, D.G.; Boerrigter, G.; Burnett, J.C., Jr.; Lark, M.W. GPCR biased ligands as novel heart failure therapeutics. Trends Cardiovasc. Med. 2013, 23, 242-249.